JP2019532069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532069A5 JP2019532069A5 JP2019520031A JP2019520031A JP2019532069A5 JP 2019532069 A5 JP2019532069 A5 JP 2019532069A5 JP 2019520031 A JP2019520031 A JP 2019520031A JP 2019520031 A JP2019520031 A JP 2019520031A JP 2019532069 A5 JP2019532069 A5 JP 2019532069A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- compound according
- disease
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 183
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 126
- 239000008194 pharmaceutical composition Substances 0.000 claims description 103
- 201000010099 disease Diseases 0.000 claims description 63
- 208000035475 disorder Diseases 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 59
- -1 N-acylethanolamide compound Chemical class 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 150000002430 hydrocarbons Chemical group 0.000 claims description 16
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 150000001200 N-acyl ethanolamides Chemical class 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- HBMSIPLIFIVUKZ-UHFFFAOYSA-N Palmitinsaeure-propylamid Natural products CCCCCCCCCCCCCCCC(=O)NCCC HBMSIPLIFIVUKZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 8
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 230000005176 gastrointestinal motility Effects 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 3
- 239000013610 patient sample Substances 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010037779 Radiculopathy Diseases 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 206010041349 Somnolence Diseases 0.000 claims description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 230000004596 appetite loss Effects 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 230000004130 lipolysis Effects 0.000 claims description 2
- 235000021266 loss of appetite Nutrition 0.000 claims description 2
- 208000019017 loss of appetite Diseases 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 229960002446 octanoic acid Drugs 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 40
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 150000001975 deuterium Chemical group 0.000 claims 1
- 0 CCCCCCCCCCCCCCC[C@@](*)N=CC*C(CCCCCCCC=CC*=CCCCCC)=O Chemical compound CCCCCCCCCCCCCCC[C@@](*)N=CC*C(CCCCCCCC=CC*=CCCCCC)=O 0.000 description 4
- OSNAOIJEFJLEPS-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(NCCOC(CCC(OCC(CO)O)=O)=O)=O Chemical compound CCCCCCCCCCCCCCCC(NCCOC(CCC(OCC(CO)O)=O)=O)=O OSNAOIJEFJLEPS-UHFFFAOYSA-N 0.000 description 1
- GUCQUFPZDATELC-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(NCCOC(CCC(OCC(COC(CCC)=O)OC(CCC)=O)=O)=O)=O Chemical compound CCCCCCCCCCCCCCCC(NCCOC(CCC(OCC(COC(CCC)=O)OC(CCC)=O)=O)=O)=O GUCQUFPZDATELC-UHFFFAOYSA-N 0.000 description 1
- SAVIEPORGSLYFE-WQQZHNEZSA-N CCCCCCCCCCCCCCCC(NCCOC(CCC(OC[C@H]([C@H]([C@@H]1O)O)O[C@@]1(CO)O[C@H]([C@@H]([C@H]1O)O)O[C@H](CO)[C@H]1O)=O)=O)=O Chemical compound CCCCCCCCCCCCCCCC(NCCOC(CCC(OC[C@H]([C@H]([C@@H]1O)O)O[C@@]1(CO)O[C@H]([C@@H]([C@H]1O)O)O[C@H](CO)[C@H]1O)=O)=O)=O SAVIEPORGSLYFE-WQQZHNEZSA-N 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407796P | 2016-10-13 | 2016-10-13 | |
| US62/407,796 | 2016-10-13 | ||
| US201762517344P | 2017-06-09 | 2017-06-09 | |
| US62/517,344 | 2017-06-09 | ||
| PCT/US2017/056353 WO2018071679A1 (en) | 2016-10-13 | 2017-10-12 | N-acylethanolamide derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532069A JP2019532069A (ja) | 2019-11-07 |
| JP2019532069A5 true JP2019532069A5 (enExample) | 2020-11-19 |
| JP7041673B2 JP7041673B2 (ja) | 2022-03-24 |
Family
ID=61906457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520031A Active JP7041673B2 (ja) | 2016-10-13 | 2017-10-12 | Ｎ－アシルエタノールアミド誘導体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10933037B2 (enExample) |
| EP (1) | EP3526215A4 (enExample) |
| JP (1) | JP7041673B2 (enExample) |
| CN (1) | CN110023308A (enExample) |
| AU (2) | AU2017341769B2 (enExample) |
| CA (1) | CA3040258A1 (enExample) |
| WO (1) | WO2018071679A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017341769B2 (en) * | 2016-10-13 | 2021-11-11 | Carnot, Llc | N-Acylethanolamide derivatives and uses thereof |
| WO2019213333A1 (en) * | 2018-05-04 | 2019-11-07 | Carnot2, Llc | Combination therapies with edaravone and prodrugs of edaravone that are orally bioavailable and have altered pharmacokinetic properties |
| WO2019213335A1 (en) * | 2018-05-04 | 2019-11-07 | Carnot2, Llc | Orally bioavailable prodrugs of edaravone with altered pharmacokinetic properties and methods of use thereof |
| US20220162239A1 (en) * | 2019-02-21 | 2022-05-26 | Université Claude Bernard Lyon 1 | Structured molecular vectors for anti-inflammatory compounds and uses thereof |
| GB202103884D0 (en) | 2021-03-19 | 2021-05-05 | Eliem Therapeutics Uk Ltd | Novel process |
| CN113304683B (zh) * | 2021-06-17 | 2022-12-13 | 江南大学 | 葡糖酰胺封端聚醚型表面活性剂、其制备方法及应用 |
| WO2025185743A1 (en) * | 2024-03-07 | 2025-09-12 | Centre for Chinese Herbal Medicine Drug Development Limited | N-oleoylethanolamide and eubacterium rectale for use in treating diarrhea-predominant irritable bowel syndrome |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2440361A (en) * | 1947-08-12 | 1948-04-27 | Lilly Co Eli | Process and culture media for the production of penicillin |
| DE4127471A1 (de) * | 1991-08-20 | 1993-02-25 | Henkel Kgaa | Verwendung von aminoalkanolamidestern als verarbeitungshilfsmittel fuer thermoplastische kunststoffe |
| IT1271623B (it) * | 1994-03-21 | 1997-06-04 | Lifegroup Spa | N-acilderivati di aminoalcoli con acidi monocarbossilici e bicarbossilici con attivita' neuroprotettiva nelle patologie neurologiche correlate ad eccitotossicita' |
| IT1271266B (it) * | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
| JP4015710B2 (ja) * | 1995-05-31 | 2007-11-28 | 生化学工業株式会社 | 新規擬似糖脂質 |
| NZ336538A (en) * | 1996-10-15 | 2001-11-30 | Liposome Co Inc | N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
| ID29246A (id) | 1999-03-11 | 2001-08-16 | Ardenia Investments Ltd | Senyawa-senyawa baru untuk pengobatan kanker |
| ATE243701T1 (de) | 1999-03-16 | 2003-07-15 | Ardenia Investments Ltd | Polyungesättigte fettsäurederivate und deren verwendung in der krebsbehandlung |
| US7090903B2 (en) * | 2002-10-07 | 2006-08-15 | Konica Corporation | Ink-jet recording sheet |
| JP2004268437A (ja) | 2003-03-10 | 2004-09-30 | Konica Minolta Holdings Inc | インクジェット記録用紙 |
| FR2925491B1 (fr) | 2007-12-19 | 2010-09-03 | Oz Biosciences Sas | Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules |
| ITMI20122127A1 (it) * | 2012-12-13 | 2014-06-14 | Epitech Group Srl | Derivati polietilenglicolici di palmitoiletanolammide e aciletanolammidi analoghe |
| EP3003331A4 (en) | 2013-06-07 | 2017-02-22 | Loma Linda University | Dietary omega-3 fatty acid derived glycerophospholipids to treat neuropathic pain |
| AU2017341769B2 (en) | 2016-10-13 | 2021-11-11 | Carnot, Llc | N-Acylethanolamide derivatives and uses thereof |
-
2017
- 2017-10-12 AU AU2017341769A patent/AU2017341769B2/en not_active Ceased
- 2017-10-12 JP JP2019520031A patent/JP7041673B2/ja active Active
- 2017-10-12 EP EP17860455.9A patent/EP3526215A4/en not_active Withdrawn
- 2017-10-12 CA CA3040258A patent/CA3040258A1/en not_active Abandoned
- 2017-10-12 CN CN201780074079.4A patent/CN110023308A/zh active Pending
- 2017-10-12 WO PCT/US2017/056353 patent/WO2018071679A1/en not_active Ceased
- 2017-10-12 US US16/349,548 patent/US10933037B2/en not_active Expired - Fee Related
-
2020
- 2020-12-09 US US17/116,414 patent/US11547681B2/en active Active
-
2021
- 2021-11-26 AU AU2021273632A patent/AU2021273632A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532069A5 (enExample) | ||
| JP7041673B2 (ja) | Ｎ－アシルエタノールアミド誘導体およびその使用 | |
| US20130202629A1 (en) | Uses of phospholipid conjugates of synthetic tlr7 agonists | |
| JP2020526511A (ja) | ニコチンアミドリボシドの合成方法 | |
| US8049038B2 (en) | Carnitine conjugates of adamantanamines derivatives as dual prodrugs for various uses | |
| CN109721580B (zh) | 3-苯基-7,8-脱氢葡萄藤戊素衍生物、其制法和药物组合物与用途 | |
| JP2023501163A (ja) | ４－アミノ－イミダゾキノリン化合物及びその使用 | |
| US6936596B2 (en) | Adenosine derivatives and use thereof | |
| JP2002504068A (ja) | 改良された治療剤 | |
| CN109721579B (zh) | 7,8-脱氢葡萄藤戊素衍生物、其制法和药物组合物与用途 | |
| WO2019228319A1 (zh) | 基于肠道mct1载体蛋白设计的前药及其制备方法 | |
| JP6949098B2 (ja) | 生物利用可能なポリアミン | |
| CN102918051A (zh) | N6-(甲基二茂铁)喹唑啉-2,4,6-三胺 (h2)和其衍生物，以及用作抗菌剂、抗寄生虫剂、抗原虫和抗利什曼虫剂的药物前体 | |
| CN101541717B (zh) | 一种反式苯丙烯酸衍生物及其制备方法和应用 | |
| CN105163732A (zh) | 用于治疗眼科疾病和病症的方法 | |
| JPH09510467A (ja) | 興奮毒性に関連した神経病理学的な状態において神経保護作用を行う薬剤の製造におけるアミノアルコールのｎ−アシル誘導体の使用 | |
| CN105330708B (zh) | 延胡索乙素衍生物及其制备方法、用途 | |
| JP2022514084A (ja) | ６，８－ビス－ベンジルチオ－オクタン酸を使用する経口療法 | |
| WO2011147254A1 (zh) | 苯丁酰基姜黄素衍生物及其在制备抗肿瘤药物中的应用 | |
| CN103037842B (zh) | 药物化合物 | |
| JP2019524654A (ja) | 新しいタイプのタキサン化合物、その製造方法および適用 | |
| TW202114650A (zh) | 6,8-雙(苄基磺醯基)辛酸之氘化衍生物 | |
| WO2022089600A1 (zh) | 黄酮苷-有机胺类抗微生物剂复盐化合物及其制备方法和应用 | |
| TW202114651A (zh) | 用於治療癌症之方法及含有４，６—雙（苄硫基）己酸之藥物組成物 | |
| JP2023511432A (ja) | ７－デアセチル－フォルスコリンとｐｖｐの複合体 |